1
|
Marchetti B, Spinola PG, Pelletier G and
Labrie F: A potential role for catecholamines in the development
and progression of carcinogen-induced mammary tumors: Hormonal
control of beta-adrenergic receptors and correlation with tumor
growth. J Steroid Biochem Mol Biol. 38:307–320. 1991. View Article : Google Scholar
|
2
|
Entschladen F, Drell TL IV, Lang K, Joseph
J and Zaenker KS: Tumour-cell migration, invasion, and metastasis:
Navigation by neurotransmitters. Lancet Oncol. 5:254–258. 2004.
View Article : Google Scholar
|
3
|
Antoni MH, Lutgendorf SK, Cole SW, Dhabhar
FS, Sephton SE, McDonald PG, Stefanek M and Sood AK: The influence
of bio-behavioural factors on tumour biology: Pathways and
mechanisms. Nat Rev Cancer. 6:240–248. 2006. View Article : Google Scholar :
|
4
|
Thaker PH, Lutgendorf SK and Sood AK: The
neuroendocrine impact of chronic stress on cancer. Cell Cycle.
6:430–433. 2007. View Article : Google Scholar
|
5
|
Lutgendorf SK, Sood AK and Antoni MH: Host
factors and cancer progression: Biobehavioral signaling pathways
and interventions. J Clin Oncol. 28:4094–4099. 2010. View Article : Google Scholar :
|
6
|
Cole SW, Nagaraja AS, Lutgendorf SK, Green
PA and Sood AK: Sympathetic nervous system regulation of the tumour
microenvironment. Nat Rev Cancer. 15:563–572. 2015. View Article : Google Scholar :
|
7
|
Vandewalle B, Revillion F and Lefebvre J:
Functional beta-adrenergic receptors in breast cancer cells. J
Cancer Res Clin Oncol. 116:303–306. 1990. View Article : Google Scholar
|
8
|
Draoui A, Vandewalle B, Hornez L,
Revillion F and Lefebvre J: Beta-adrenergic receptors in human
breast cancer: Identification, characterization and correlation
with progesterone and estradiol receptors. Anticancer Res.
11:677–680. 1991.
|
9
|
Slotkin TA, Zhang J, Dancel R, Garcia SJ,
Willis C and Seidler FJ: Beta-adrenoceptor signaling and its
control of cell replication in MDA-MB-231 human breast cancer
cells. Breast Cancer Res Treat. 60:153–166. 2000. View Article : Google Scholar
|
10
|
Powe DG, Voss MJ, Habashy HO, Zänker KS,
Green AR, Ellis IO and Entschladen F: Alpha- and beta-adrenergic
receptor (AR) protein expression is associated with poor clinical
outcome in breast cancer: An immunohistochemical study. Breast
Cancer Res Treat. 130:457–463. 2011. View Article : Google Scholar
|
11
|
Shi M, Liu D, Duan H, Qian L, Wang L, Niu
L, Zhang H, Yong Z, Gong Z, Song L, et al: The β2-adrenergic
receptor and Her2 comprise a positive feedback loop in human breast
cancer cells. Breast Cancer Res Treat. 125:351–362. 2011.
View Article : Google Scholar
|
12
|
Madden KS, Szpunar MJ and Brown EB:
β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by
divergent pathways in high β-AR-expressing breast cancer cell
lines. Breast Cancer Res Treat. 130:747–758. 2011. View Article : Google Scholar :
|
13
|
Barron TI, Sharp L and Visvanathan K:
Beta-adrenergic blocking drugs in breast cancer: A perspective
review. Ther Adv Med Oncol. 4:113–125. 2012. View Article : Google Scholar :
|
14
|
Zhang P, He X, Tan J, Zhou X and Zou L:
β-arrestin2 mediates β-2 adrenergic receptor signaling inducing
prostate cancer cell progression. Oncol Rep. 26:1471–1477.
2011.
|
15
|
Ji Y, Chen S, Li K, Xiao X, Zheng S and Xu
T: The role of β-adrenergic receptor signaling in the proliferation
of hemangioma-derived endothelial cells. Cell Div. 8:12013.
View Article : Google Scholar :
|
16
|
Carie AE and Sebti SM: A chemical biology
approach identifies a beta-2 adrenergic receptor agonist that
causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2
pathway. Oncogene. 26:3777–3788. 2007. View Article : Google Scholar
|
17
|
Piñero Pérez C, Bruzzone A, Sarappa MG,
Castillo LF and Lüthy IA: Involvement of α2- and β2-adrenoceptors
on breast cancer cell proliferation and tumour growth regulation.
Br J Pharmacol. 166:721–736. 2012. View Article : Google Scholar :
|
18
|
Roskoski R Jr: ERK1/2 MAP kinases:
Structure, function, and regulation. Pharmacol Res. 66:105–143.
2012. View Article : Google Scholar
|
19
|
Price DM, Chik CL and Ho AK:
Norepinephrine induction of mitogen-activated protein kinase
phosphatase-1 expression in rat pinealocytes: Distinct roles of
alpha- and beta-adrenergic receptors. Endocrinology. 145:5723–5733.
2004. View Article : Google Scholar
|
20
|
Chruscinski AJ, Singh H, Chan SM and Utz
PJ: Broad-scale phosphoprotein profiling of beta adrenergic
receptor (β-AR) signaling reveals novel phosphorylation and
dephosphorylation events. PLoS One. 8:e821642013. View Article : Google Scholar :
|
21
|
Bartholomeusz C, Gonzalez-Angulo AM, Liu
P, Hayashi N, Lluch A, Ferrer-Lozano J and Hortobágyi GN: High ERK
protein expression levels correlate with shorter survival in
triple-negative breast cancer patients. Oncologist. 17:766–774.
2012. View Article : Google Scholar :
|
22
|
Boutros T, Chevet E and Metrakos P:
Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase
regulation: Roles in cell growth, death, and cancer. Pharmacol Rev.
60:261–310. 2008. View Article : Google Scholar
|
23
|
Bermudez O, Marchetti S, Pagès G and
Gimond C: Post-translational regulation of the ERK phosphatase
DUSP6/MKP3 by the mTOR pathway. Oncogene. 27:3685–3691. 2008.
View Article : Google Scholar
|
24
|
Wu JJ, Zhang L and Bennett AM: The
noncatalytic amino terminus of mitogen-activated protein kinase
phosphatase 1 directs nuclear targeting and serum response element
transcriptional regulation. Mol Cell Biol. 25:4792–4803. 2005.
View Article : Google Scholar :
|
25
|
Zhou B, Wang ZX, Zhao Y, Brautigan DL and
Zhang ZY: The specificity of extracellular signal-regulated kinase
2 dephosphorylation by protein phosphatases. J Biol Chem.
277:31818–31825. 2002. View Article : Google Scholar
|
26
|
Zhang Z, Kobayashi S, Borczuk AC, Leidner
RS, Laframboise T, Levine AD and Halmos B: Dual specificity
phosphatase 6 (DUSP6) is an ETS-regulated negative feedback
mediator of oncogenic ERK signaling in lung cancer cells.
Carcinogenesis. 31:577–586. 2010. View Article : Google Scholar :
|
27
|
Brondello J, Brunet A, Pouysségur J and
Mckenzie FR: The dual specificity mitogen-activated protein kinase
phosphatase-1 and −2 are induced by the p42/p44MAPK cascade. J Biol
Chem. 272:1368–1376. 1997. View Article : Google Scholar
|
28
|
Chen J, Martin BL and Brautigan DL:
Regulation of protein serine-threonine phosphatase type-2A by
tyrosine phosphorylation. Science. 257:1261–1264. 1992. View Article : Google Scholar
|
29
|
Guo CY, Brautigan DL and Larner JM:
Ionizing radiation activates nuclear protein phosphatase-1 by
ATM-dependent dephosphorylation. J Biol Chem. 277:41756–41761.
2002. View Article : Google Scholar
|
30
|
Candas D, Lu CL, Fan M, Chuang FY, Sweeney
C, Borowsky AD and Li JJ: Mitochondrial MKP1 is a target for
therapy-resistant HER2-positive breast cancer cells. Cancer Res.
74:7498–7509. 2014. View Article : Google Scholar :
|
31
|
Haagenson KK, Zhang JW, Xu Z, Shekhar MP
and Wu GS: Functional analysis of MKP-1 and MKP-2 in breast cancer
tamoxifen sensitivity. Oncotarget. 5:1101–1110. 2014. View Article : Google Scholar :
|
32
|
Nunes-Xavier C, Romá-Mateo C, Ríos P,
Tárrega C, Cejudo-Marín R, Tabernero L and Pulido R:
Dual-specificity MAP kinase phosphatases as targets of cancer
treatment. Anticancer Agents Med Chem. 11:109–132. 2011. View Article : Google Scholar
|
33
|
Hill TA, Stewart SG, Sauer B, Gilbert J,
Ackland SP, Sakoff JA and McCluskey A: Heterocyclic substituted
cantharidin and norcantharidin analogues-synthesis, protein
phosphatase (1 and 2A) inhibition, and anti-cancer activity. Bioorg
Med Chem Lett. 17:3392–3397. 2007. View Article : Google Scholar
|
34
|
Winter SL, Bosnoyan-Collins L, Pinnaduwage
D and Andrulis IL: The interaction of PP1 with BRCA1 and analysis
of their expression in breast tumors. BMC Cancer. 7:852007.
View Article : Google Scholar :
|
35
|
Brand TM, Iida M and Wheeler DL: Molecular
mechanisms of resistance to the EGFR monoclonal antibody cetuximab.
Cancer Biol Ther. 11:777–792. 2011. View Article : Google Scholar :
|
36
|
Wu W, Pew T, Zou M, Pang D and Conzen SD:
Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1)
expression inhibits paclitaxel-associated MAPK activation and
contributes to breast cancer cell survival. J Biol Chem.
280:4117–4124. 2005. View Article : Google Scholar
|
37
|
Swingle M, Ni L and Honkanen RE:
Small-molecule inhibitors of ser/thr protein phosphatases:
Specificity, use and common forms of abuse. Methods Mol Biol.
365:23–38. 2007.
|